Phase II Study of BBR 3464 as Treatment in Patients with Sensitive or Refractory Small Lung Cancer after one Prior Chemotherapy Regimen

Grants and Contracts Details

StatusFinished
Effective start/end date11/1/006/30/02

Funding

  • Theradex: $1,850.00